SWTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SWTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. SpringWorks Therapeutics's Revenue for the three months ended in Mar. 2024 was $21.01 Mil. SpringWorks Therapeutics's average Accounts Receivable for the three months ended in Mar. 2024 was $10.73 Mil. Hence, SpringWorks Therapeutics's Receivables Turnover for the three months ended in Mar. 2024 was 1.96.
The historical data trend for SpringWorks Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SpringWorks Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Receivables Turnover | Get a 7-Day Free Trial | - | - | - | - | 0.92 |
SpringWorks Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Receivables Turnover | Get a 7-Day Free Trial | - | - | - | 0.92 | 1.96 |
For the Biotechnology subindustry, SpringWorks Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, SpringWorks Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where SpringWorks Therapeutics's Receivables Turnover falls into.
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
SpringWorks Therapeutics's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Receivables Turnover (A: Dec. 2023 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (A: Dec. 2023 ) | / ( | (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) |
= | 5.447 | / ( | (0 | + | 5.93) | / | 1 ) |
= | 5.447 | / | 5.93 | ||||
= | 0.92 |
SpringWorks Therapeutics's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as
Receivables Turnover (Q: Mar. 2024 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (Q: Mar. 2024 ) | / ( | (Accounts Receivable (Q: Dec. 2023 ) | + | Accounts Receivable (Q: Mar. 2024 )) | / | count ) |
= | 21.006 | / ( | (5.93 | + | 15.529) | / | 2 ) |
= | 21.006 | / | 10.7295 | ||||
= | 1.96 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SpringWorks Therapeutics (NAS:SWTX) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Thank you for viewing the detailed overview of SpringWorks Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Tai-an Lin | officer: Chief Scientific Officer | C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BOULEVARD, STAMFORD CT 06902 |
Julie Hambleton | director | C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Jeffrey Lawrence Schwartz | director, 10 percent owner | C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116 |
Daniel Pichl | officer: Chief People Officer | C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902 |
James Cassidy | officer: Chief Medical Officer | 368 NOD HILL ROAD, WILTON CT 06897 |
Orbimed Advisors Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carlos Alban | director | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Saqib Islam | director, officer: Chief Executive Officer | ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
L. Mary Smith | officer: See Remarks | C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902 |
Bain Capital Life Sciences Investors, Llc | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Michael F. Burgess | officer: Head of Research & Development | C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142 |
Stephen P Squinto | director, 10 percent owner | C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Bhavesh Ashar | officer: Chief Commercial Officer | C/O SPRINGWORKS THERAPEUTICS, 100 WASHINGTON BLVD, STAMFORD CT 05902 |
Orbimed Capital Gp Vi Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Badreddin Edris | officer: Chief Business Officer | C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902 |
From GuruFocus
By PRNewswire PRNewswire • 11-01-2022
By Marketwired • 09-11-2023
By Tiesvg Tiesvg • 12-27-2022
By Stock market mentor Stock market mentor • 01-03-2023
By sperokesalga sperokesalga • 05-30-2023
By Marketwired • 08-02-2023
By sperokesalga sperokesalga • 05-03-2023
By sperokesalga sperokesalga • 04-17-2023
By sperokesalga sperokesalga • 06-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.